JPX and LINC00641 ncRNAs expression in prostate tissue: a case-control study

Roshanak S. Sajjadi1, Mohammad Hossein Modarressi2, and Mohammad Amin Tabatabaiefar1,3,*

1Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
2Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, I.R. Iran.
3Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Noncommunicable Disease, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

Abstract

Background and purpose: Prostate cancer (PC) is the second most prevalent cancer in men. Prostate-specific antigen (PSA) is the main biomarker for screening PC. An increase in PSA could lead to false-positive results. Thus, more appropriate markers should be investigated. In the present study, JPX and LINC00641 expression levels were measured in tumoral prostate tissue compared with the non-tumor tissue.

Experimental approach: 43 pairs of prostate tumoral and non-tumor tissue were prepared. The expression levels of JPX and LINC00641 were investigated by RT-qPCR.

Findings/Results: Significant upregulation of LINC00641 (2.47 ± 0.5 vs 1.41 ± 0.2) and downregulation of JPX (1.42 ± 0.6 vs 2.83 ± 1.0) were observed in PC tissues compared with the normal tissues (their adjacent non-tumor tissues).

Conclusion and implications: Dysregulation of JPX and LINC00641 in PC patients could be used in the future as a prognostic biomarker in PC.

Keywords: Gene expression; JPX; LINC00641; Long non-coding RNA; Prostate cancer.

INTRODUCTION

Prostate cancer (PC) has been reported as the most prevalent malignancies in the male in the world. Many studies have shown that the incidence of PC is increasing significantly in recent years. About 42% of this type of cancer occurs in men over the age of 50 and most cases over the age of 60 years (1).

Commonly used PC screening methods are prostate-specific antigen (PSA) and digital rectal examination, and confirmation is based on biopsy (2). The Gleason scoring (GS) system is the most common PC grading system used, in which the cells with more transformation receive a higher score (3,4). Other clinical features reported with biopsy results include tumor involvement, PSA level, perineural invasion, prostatic intraepithelial neoplasia (PIN), apex and base, circumferential margins & capsule, and seminal vesicles (5). Usually, PSA levels above 4 ng/mL are assumed to be suspected. As levels increase higher than 10.0 ng/mL, the risk of cancer increases significantly. PSA level of 10 ng/mL is considered to be a cutoff level for performing the bone scan (6). However, none of them alone will be an absolute sign of progress, although GS is the most important item (7).
Although the use of PSA as a marker is highly sensitive for diagnosing PC, it lacks sufficient specificity, as it can be high in benign prostate hyperplasia (BPH) and prostatitis. Therefore, PSA has a high false-positive rate leading to unnecessary biopsy and inappropriate treatment. Based on previous studies, it has been shown that two-thirds of the performed biopsies were not, in effect, necessary (1). Current techniques for the staging of PC cannot differentiate between indolent (which needs no treatment) and highly invasive, fatal tumors. Since there is no effective treatment available for patients with high-grade cancer, it is necessary to accurately specify the degree of malignancy of the PC (8).

The main mechanism(s) through which initiation of PC occurs are not well defined yet. The androgen receptor signaling pathway is one of the main pathways involved in PC initiation and progression. Three other signaling pathways that are common in PC include RAS/RAF, RB, and phosphoinositide 3-kinases (PI3K) pathways (9). The dysfunction of PI3K signaling pathway has been shown in 42% of patients with primary and in 100% of metastatic patients with PC. The protein kinase B (PKB/Akt) is the main intermediate of the oncogenic effect of PI3K. The two essential genes in this pathway with the highest mutations include INPP4B and PTEN. Mutation of INPP4B and PTEN are found in 42% and 47% of metastatic patients, respectively (9). PTEN is a tumor suppressor and antagonist of the PI3K/Akt pathway, which has an inhibitory function by the phosphatase effect in this pathway. The precise functional mechanism of INPP4B is not exactly determined, but some evidence suggests that it can also have a tumor suppressor role. Mutated INPP4B and PTEN lead to full activation of Akt (10).

In addition to studying markers such as receptors in cancer (11), one of the molecules that have been regarded recently to be involved in malignancy is long non-coding RNA (lncRNA). LncRNAs have been shown to perform key functions in the cell, including splicing, gene expression regulation, cell growth, differentiation, and epigenetic processes (12,13). Another role of lncRNAs is related to small non-coding RNAs including microRNAs (miRNAs). Recent studies emphasize that lncRNAs work as competing endogenous RNAs (ceRNAs) to control mRNAs through miRNAs, which indicates a novel layer of RNA crosstalk. However, the main regulation and characterization of this sort of crosstalk in cancers are still mainly unknown (14).

LncRNAs through their sponge role cause trapping and destruction of miRNAs. Consequently, they inhibit miRNA function (15). Also, lncRNAs with no protein-coding capability have key roles in the initiation and progression of tumors through modifying oncogenic and tumor-suppressing pathways (16). They can affect multiple signaling pathways for tumor invasion, progression, metastasis, and chemotherapy resistance. The characteristics of these molecules have led researchers to investigate the lncRNA-disease association, especially in cancers (17,18). In recent years, in silico bioinformatic studies have been applied to clarify the etiology and treatment of complex disorders such as cancer (19,20). Here, we used a customized pipeline to select and identify lncRNA by using a variety of bioinformatics software and databases such as HMDD (www.cuilab.cn/hmdd), starBase (www.starbase.sysu.edu.cn/), MNDR (www.rna-society.org/mndr/), LncRNA Disease (www.cuilab.cn/lncrnadisease), DIANATools (http://diana.imis.athena-innovation.gr/DianaTools/index.php), Lnc2Cancer (www.biobigdata.net/Lnc2cancer/).

Finally, in this study, a couple of lncRNA including LINC00641 and JPX revealed through in silico analysis, were selected for expression analysis. Both of them were selected for expression analysis in the prostate tumor tissue compared to the non-tumoral adjacent tissue. Furthermore, the correlation between lncRNAs and pathologic factors of PC was investigated to assess their potential as tumor markers for PC detection. LncRNAs were selected according to a customized pipeline, which involved a combination of two methods. Method A was based on the important signaling pathway in the PC. Method B was performed with HGLDA, a computational model based on the selection of lncRNAs. We aimed to evaluate

494
the dysregulation of LINC00641 and JPX in PC tumor tissues and their adjacent tissues and to assess their correlation with other characteristics of PC to eventually evaluate their potential as tumor markers for PC tracing in future studies.

**MATERIALS AND METHODS**

**In silico study**

According to the designed pipeline in our previous study (unpublished results), several lncRNAs relevant to PC with \( P \)-values less than 0.05 were selected. Based on the NONCODE database, LINC00641 and JPX showed an appropriate expression in the prostate. In addition, both of them have many target miRNAs in the PI3K/AKT pathway. In this experimental study, these lncRNAs were selected for expression analysis in prostate tumor tissue of affected individuals and adjacent non-tumoral tissue. Table 1 presents the sequences of our designed oligonucleotide primers.

**Tissue sample collection**

In this study, after collecting informed consent, all patients were selected based on the inclusion criteria: the histopathological results of the needle biopsy specimens supported PC or BPH, with no chemotherapy administered prior to surgery. Table 2 presents the characteristics of the patients. Fresh tumor tissues and their adjacent non-tumoral tissues were obtained from PC patients and were directly frozen in liquid nitrogen and then stored at -80 °C until RNA extraction.

### Table 1. Nucleotide sequences of the primers used for the real-time polymerase chain reaction.

| Primer name  | Sequences                              | Product size (bp) |
|--------------|----------------------------------------|-------------------|
| Linc00641    | Forward: AAATTCTGATGTCCAGTGCCATG       | 268               |
| Linc00641    | Reverse: CAGATGAACAGCCGGGCAC            |                   |
| JPX          | Forward: GTCCGAAGTAGTACTCCACTAAC        | 147               |
| JPX          | Reverse: CGAAACTCATCTCTTCTGCACT        |                   |
| ACTB         | Forward: AGAGCTACGAGCTGCCTGAC          | 184               |
| ACTB         | Reverse: AGCACTGTGTGGCGGTACAG          |                   |

### Table 2. Clinical characteristics of patients.

| Characteristics                        | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|----------------------------------------|---------|---------|---------|---------|---------|
| Gleason score (GS)                     | Non-cancer | benign prostate hyperplasia | GS 6 | GS 7 | GS 8-10 |
| Sample size                            | 43       | 5       | 10      | 23      | 10      |
| Age (min-max)                          | 52-83    | 60-78   | 56-77   | 52-81   | 56-83   |
| ≤ 60                                   | 11       | 0       | 3       | 6       | 2       |
| > 60                                   | 32       | 5       | 7       | 17      | 8       |
| Tumor involvement                      | One side | -       | 4       | 8       | 3       |
|                                        | Two side | -       | 6       | 15      | 7       |
| PSA level (ng/mL)                      | PSA < 10 | -       | 8       | 15      | 6       |
|                                        | PSA ≥ 10 | -       | 2       | 8       | 5       |
| Perineurial invasion                   | Negative | -       | 4       | 2       | 2       |
|                                        | Positive | -       | 6       | 21      | 8       |
| Prostatic intraepithelial neoplasia    | Negative | -       | 2       | 5       | 2       |
|                                        | Positive | -       | 8       | 18      | 8       |
| Apex and base                          | Free     | -       | 8       | 19      | 7       |
|                                        | Involved | -       | 2       | 4       | 3       |
| Circumferential margins and capsule    | Free     | -       | 7       | 21      | 7       |
|                                        | Involved | -       | 3       | 2       | 3       |
| Seminal vesicles                       | Free     | -       | 8       | 20      | 6       |
|                                        | Involved | -       | 2       | 3       | 4       |
Table 3. Used material in real-time polymerase chain reaction.

| Material                          | Volume (µL) |
|----------------------------------|-------------|
| 2X SYBR Green master mix         | 5 µL        |
| cDNA samples                     | 1 µL        |
| Forward and reverse primers (2 pmol) | 0.5 µL      |
| Nuclease-free water              | 3 µL        |

Table 4. Thermal cycling conditions.

| Initial activation | Denaturation | Annealing/extension |
|--------------------|--------------|---------------------|
| (40 cycles)        | (40 cycles)  |                     |
| 30 s at 95 °C      | 5 s at 95 °C | 20 s at 60 °C        |

All tests were accomplished in conformity with relevant instructions. First, from each patient, written informed consent was received. All the clinical samples were obtained from Imam Khomeini Hospital of Tehran University of Medical Sciences. The Review Board of Isfahan University of Medical Sciences approved this study (Ethics code: IR.MUI.REC.1396.3.123).

RNA extraction, cDNA synthesis, and quantitative real-time polymerase chain reaction

According to the manufacturer’s instructions, the total RNA purification kit (Norgen, Canada), total RNA isolation was performed from tissue samples. The quantity of RNA was evaluated spectrophotometrically by Nanodrop ND-2000 (Thermo Fisher Scientific, USA). Then, 1 µg of the extracted RNA was reverse transcribed into cDNA using the PrimeScript II first-strand cDNA synthesis kit (Takara, Japan), according to the instructions of the manufacturer. Quantitative real-time polymerase chain reaction (qRT-PCR) was assessed on the Rotor-Gene Q 5plex HRM system (Qiagen, Germany) using SYBR Premix Ex Taq II (Tli RNaseH Plus, Takara, Japan). The protocol detailed in Table 3 was applied to perform PCR in 10 µL reaction volumes. Thermal cycling conditions were set as shown in Table 4. The specificity of the target PCR product was confirmed by visualizing a single peak in the melting curve analysis. Beta-actin (ACTB) was used as a reference gene. qRT-PCR data analysis was accomplished based on the 2^ΔΔct comparative expression method (21).

Statistical analysis

All tests were performed in duplicate and the mean values were calculated. In the result section, each column of data has been shown as mean ± SEM. Wilcoxon, Mann Whitney U, and Kruskal-Wallis tests were used for comparison of the control and tumor groups in terms of different grades of the tumor using SPSS (version 25.0), and GraphPad Prism (version 6.0) software tools. In all tests, P < 0.05 indicated a significant difference.

RESULTS

Upregulation of LINC00641 in prostate tissue of patients

Levels of LINC00641 expression were evaluated in the tissue samples of 43 patients diagnosed with different grades of PC and in their adjacent non-tumoral tissues. Also, they were assessed in 5 tissue samples of patients diagnosed with BPH. As shown in Fig. 1A, LINC00641 expression levels were significantly higher in the PC group (case) than in the non-tumoral group (control) (2.47 ± 0.5 vs 1.41 ± 0.2). To investigate the prognostic significance of LINC00641 in PC patients, the mean expression values were evaluated compared with available clinicopathological features (Table 5). The expression levels of LINC00641 were investigated in four groups including cancerous tissues with GSs 6, 7, 8-10 and BPH. LINC00641 showed the highest expression levels in the BPH group. In cancerous tissues, this increase was found to be higher as Gleason scores advanced (Fig. 1B). The expression levels significantly differed between GS 6 and BPH groups, between GS 7 and BPH and finally between GSs 8-10 and BPH. In other words, based on the results illustrated in Fig. 1C and considering all cancer samples in a group, the LINC00641 could differentiate cancer samples from BPH. Fig. 1D shows LINC00641 expression in control and case groups in low GS in PC tissues.

Downregulation of JPX in the prostate tissue

JPX expression levels were evaluated in tissue samples of 43 patients diagnosed with different grades of PC and in their adjacent non-tumoral tissues. Also, they were assessed in 5 tissue samples of patients diagnosed with BPH.
As shown in Fig. 2A, JPX expression level was significantly lower in the PC group (case) than in non-tumoral samples (control) (1.42 ± 0.6 vs 2.83 ± 1.0).

To investigate the prognostic significance of JPX in PC patients, we evaluated the association of its mean expression with available clinicopathological features of our patients (Table 6).

The expression level of JPX was investigated in four groups including cancerous tissues with GSs 6, 7, 8-10 and BPH. Fig. 2B shows that the amount of JPX expression level in the BPH group is the lowest among the groups, and its expression in cancerous tissues varies; while it is low in tissues with GS 6, the expression is increased in samples with GS 7 but descends in GS 8-10.

**Table 5.** Association of LINC00641 expression levels and clinicopathological characteristics of prostate cancer samples. Values represent means ± SEM.

| Characteristics                      | Mean ± SEM | P-value |
|--------------------------------------|------------|---------|
| Age (min-max)                        |            |         |
| ≤ 60                                 | 3.74 ± 1.7 | 0.7     |
| > 60                                 | 2.0 ± 0.2  |         |
| Tumor involvement                    |            | 0.2     |
| One side                             | 2.96 ± 1.4 |         |
| Two side                             | 2.21 ± 0.2 |         |
| Prostate-specific antigen level (ng/mL) |          | 0.3     |
| PSA < 10                             | 2.87 ± 1.0 |         |
| PSA ≥ 10                             | 2.16 ± 0.38|         |
| Perineurial invasion                 |            | 0.1     |
| Negative                             | 1.205 ± 0.35|        |
| Positive                             | 2.73 ± 0.6 |         |
| Prostatic intraepithelial neoplasia  |            | 0.9     |
| Negative                             | 2.07 ± 0.5 |         |
| Positive                             | 2.53 ± 0.5 |         |
| Apex and base                        |            | 0.1     |
| Free                                 | 2.46 ± 0.6 |         |
| Involved                             | 2.58 ± 0.3 |         |
| Circumferential margins and capsule  |            | 0.3     |
| Free                                 | 2.56 ± 0.5 |         |
| Involved                             | 1.33 ± 0.6 |         |
| Seminal vesicles                     |            | 0.8     |
| Free                                 | 2.52 ± 0.5 |         |
| Involved                             | 1.97 ± 0.7 |         |
Fig. 2. (A) JPX expression in prostate cancer tissues and their adjacent noncancerous tissues; and (B) the expression levels of JPX in different groups. Values represent means ± SEM. *P < 0.05 indicates significant differences in comparison with the control group.

Table 6. Association of JPX expression levels and clinicopathological characteristics of prostate cancer samples. Values represent means ± SEM.

| Characteristics                        | Mean ± SEM | P-value |
|----------------------------------------|------------|---------|
| Age (min-max)                          |            |         |
| ≤ 60                                   | 1.07 ± 0.4 | 0.5     |
| > 60                                   | 1.5 ± 0.8  |         |
| Tumor involvement                      |            |         |
| One side                               | 0.6 ± 0.2  | 0.2     |
| Two side                               | 1.84 ± 0.9 |         |
| PSA level (ng/mL)                      |            |         |
| PSA < 10                               | 2.02 ± 1.1 | 0.5     |
| PSA ≥ 10                               | 0.5 ± 0.1  |         |
| Perineurial invasion                   |            |         |
| Negative                               | 0.65 ± 0.1 | 0.5     |
| Positive                               | 1.5 ± 0.7  |         |
| Prostatic intraepithelial neoplasia    |            |         |
| Negative                               | 0.2 ± 0.05 | 0.07    |
| Positive                               | 1.6 ± 0.7  |         |
| Apex and base                          |            |         |
| Free                                   | 1.37 ± 0.8 | 0.06    |
| Involved                               | 1.61 ± 0.5 |         |
| Circumferential margins and capsule    |            |         |
| Free                                   | 1.48 ± 0.7 | 0.4     |
| Involved                               | 0.8 ± 0.2  |         |
| Seminal vesicles                       |            |         |
| Free                                   | 1.4 ± 0.6  | 0.6     |
| Involved                               | 1.6 ± 0.9  |         |

DISCUSSION

PC is the most prevalent malignancy in men. Several studies have revealed that the incidence has increased dramatically in recent years (1). PC is caused by a combination of both genetic and epigenetic changes converting the natural gland epithelium to pre-neoplastic lesions and ultimately to invasive cancer (17,22). PSA and digital rectal examination are screening tests for PC. However, in some conditions such as BPH, PSA levels are also increased, which may lead to unnecessary prostate biopsy resulting in additional costs, anxiety, and pain. Thus, other biomarkers are needed to be sought for possible diagnosis, prognosis, and management of PC (17).

One of the emerging biomarkers is lncRNA, which plays a key role in biological functions and regulating gene expression at different levels. IncRNAs have remarkable advantages over proteins. Although they have low
expression levels, they are of high tissue specificity and can be detected even at very low levels and in any type of sample (23). Also, many IncRNAs are related to different types of cancers including breast cancer, glioblastoma, colorectal cancer, liver cancer, and leukemia (24). The PI3K/Akt/mTOR pathway has multiple cellular activities including cell survival, growth, proliferation, cell migration, and invasion (25). Experimental studies indicate that the pathway is necessary for the survival of the cancer stem cell population and participates in epithelial-to-mesenchymal transition (EMT) in PC cells. Also, many studies have shown that the PI3K/AKT pathway is one of the most common pathways altered in cancers such as PC (26). PTEN and INPP4B are two components of the PI3K/AKT signaling pathway whose loss of function leads to PC (27,28). Therefore, the PI3K/AKT/mTOR pathway is essential to the metastatic potential of PC and presents considerable evidence for targeting the PI3K/AKT/mTOR pathway in this disease (29).

In this study, two IncRNAs, JPX and LINC00641, identified via in silico methods, were investigated in PC. After the construction of the ceRNA network via the Cytoscape v3.2.1 software, based on the interaction between genes, miRNAs, and IncRNAs associated with the disease, the selected IncRNAs are expected to be associated with the progression of PC (Fig. 3). All items in the network have been reported in association with cancer, especially PC. Several important aspects of the network are discussed below.

Within the nucleus, forkhead box transcription factors (FOXO) lead to apoptosis through the induction of death genes such as the FasL gene. Studies suggest that FOXOs are the main mediators of tumor suppression downstream of PTEN, and are dysregulated in many tumor types including breast cancer, PC, glioblastoma, rhabdomyosarcoma, and leukemia (30).

Improper expression of anti-apoptotic members of the BCL2 gene family has also been shown in human cancers and leukemias. BCL2 family proteins control all main types of cell death, such as necrosis, autophagy, and apoptosis, hence playing a role as a major factor in several pathways associated with oncology. The upregulation of BCL2 has been documented in many cancer types. BCL2 inhibits apoptosis by interacting with pro-apoptotic members of the BCL2 family, such as BAX, BAD, and BID. BCL2 is overexpressed in androgen-independent PC (31).

**Fig. 3.** Predicted IncRNAs-related ceRNA network in prostate cancer by Cytoscape v3.2.1 software. The V shapes represent IncRNAs.
**ERBB2** encodes a member of the epidermal growth factor receptor family of receptor tyrosine kinases. Overexpression of this gene has been shown in many cancers, including ovarian and breast tumors. It has been indicated that ERBB2 activates androgen receptor signaling at the molecular level, even in the presence of low levels of androgen (32).

Notch signaling is involved in controlling the balance between apoptosis, cell proliferation, and differentiation. The Notch gene is aberrantly overexpressed in many human cancers. It has been demonstrated that the Notch signaling participates in PC cell survival and Notch-related genes are overexpressed in PC. In human PC tissues, Notch expression level is raised with increasing tumor grade (33).

**MYC** is a proto-oncogene and encodes a nuclear phosphoprotein participating in the cell cycle progression, apoptosis, and cellular transformation. Changes in chromosome 8q24 engulfing MYC have also been associated with disease severity. MYC appears to be overexpressed at the earliest phases of PC, from prostatic intraepithelial neoplasia to advanced prostatic adenocarcinoma (34).

The diagnostic value of miR-378 is more than that of the commonly used markers including carcinoembryonic antigen and CA19-9, suggesting the high confidence of miRNA-378 as a primary diagnosing biomarker of malignancy. According to a meta-analysis, miRNA-378 has a specificity of 74% and a sensitivity value of 75% in differentiating individuals with cancer from healthy people. miRNA-378 is overexpressed and appears to act as an oncogene in ovarian cancer, liver cancer, nasopharyngeal carcinoma, human breast cancer, colorectal cancer, gastric cancer, and renal cell carcinoma. However, in vitro assays investigating the antiproliferative function of miRNA-378 in PC have revealed that the upregulation of miRNA-378 suppresses PC cell migration, invasion, and induces cell apoptosis (35).

Regarding the function of miRNA families in SLUG regulation, it has been reported that there is a mutually repressive interaction between miRNA-1 and miRNA-200 with SLUG, which is an anti-apoptotic protein. SLUG overexpression together with miRNA-1 and miRNA-200b downregulation are needed to induce EMT and mesenchymal differentiation in cancer. Also, studies show that miRNA-1 and miRNA-200 inhibit a variety of mesenchymal attributes and growth rates in invasive human PC cells. On the other hand, miRNA-200b and miRNA-200c transfections significantly diminished the expression of Notch (36).

miRNA-153 has been suggested as a promising tumor-associated miRNA and is dramatically dysregulated in cancers. The miRNA-153 expression is decreased in human oral cancer, glioblastoma, ovarian cancer, and breast cancer. In these cancers, miRNA-153 leads to cell apoptosis by directly suppressing anti-apoptosis family member BCL2. In PC, however, miRNA-153 represses PTEN expression to activate AKT kinase (37).

Hence, this network can provide evidence for molecular abnormalities and expression dysregulation in PC and suggests new candidate interactions that could be involved in PC etiology.

In our model, **PTEN** and **INPP4B** are the primary target genes of our selected lncRNAs. Thus, we evaluated the expression levels of lncRNAs with putative roles in the regulation of the PI3K/AKT signaling pathway. The results of the present study showed a significant upregulation of LINC00641 in PC samples compared to the adjacent non-cancerous tissues. Moreover, our data showed that the expression level of JPX is decreased in PC samples compared to the adjacent non-cancerous tissues. Notably, the prediction of these lncRNAs was initially based on the PI3K/AKT pathway (genes and related miRNAs). In our work, after adding other important genes and miRNAs associated with PC from the literature, as well as including the information from integrated databases such as TCGA, DIANA tool, starBase, and HMDD, other interactions and effects of these lncRNAs in the disease were inferred. In the other words, this 3-layer network consisting of PC-related miRNAs, miRNAs, and lncRNAs revealed the potential relationship between these components and pathways involved in the PC.
The use of lncRNAs as PC biomarkers is in its infancy. Currently, the only Food and Drug Administration (FDA)-approved test is PCA3. Marks et al. were the first to evaluate the PCA3 in 226 patients who had undergone a biopsy and showed its superiority to PSA. However, the PCA3 scores did not distinguish between high-grade and low-grade tumors. Besides, patients with low-grade tumors normally present too low PCA3 value to be detected (38).

JPX is located 10 kb upstream of XIST and activates it through making a balance between its activators and repressors (39). Therefore, the decrease in JPX expression could cause the loss of XIST, leading to X reactivation and altered expression of cancer-associated genes in the X chromosome, which may cause cancers. On the other hand, XIST is associated with β-catenin signaling, which induces EMT. Besides, EMT is involved in the progression of cancer metastasis. Hence, JPX may cause the development of cancers such as PC through the regulation of the XIST function (40,41). Thus far, few investigations have been performed on the association between JPX and cancer. In 2016, a study by Weijema et al. demonstrated a significant reduction in JPX expression in hepatocellular carcinoma. Their study was based on the investigation of the expression of this lncRNA in the tumoral tissue of the liver compared to the expression in the adjacent normal tissue (42). This study could be regarded as a clue for our findings. Also, overexpressed JPX increases the proliferation and invasion of human ovarian cancer cells, and prevents apoptosis by stimulating the PI3K/AKT/mTOR signaling (43). Recently, studies have been demonstrated that as an oncogene, JPX is significantly overexpressed in non-small-cell lung cancer tissues and is related to poor prognosis. JPX leads to cyclin D2 overexpression in the ceRNA mechanism by interacting with miRNA-145-5p leading to non-small-cell lung cancer development and progression (44). On the other hand, JPX acts as an oncogene to increase the risk of ovarian and lung cancer. On the other hand, JPX performs as a tumor suppressor gene to inhibit hepatocellular carcinoma development (45).

In this study, we assessed the correlation between JPX and the tumor features of PC through the GS. Although the reduced expression was not statistically significant, the reduction trend was more pronounced in the initiation (tumors of the lowest GSs) and advanced forms (tumors of highest GSs) of PC. In case this is established in a future study with more sample size, it could be concluded that JPX plays a role in the initiation and invasion of cancer. As there is a preference for the increased expression of biomarkers over their reduction, in future studies, the expression of molecules such as miRNAs that are either upstream or downstream of JPX can be evaluated. On the other hand, many studies have suggested markers showing reduced expression in the disease (46).

There was no significant difference between clinicopathology subcategories in terms of JPX expression. However, JPX reducing expression trend was seen in PSA ≥ 10 (ng/mL) group and the involved circumferential margins and capsule group compared to PSA < 10 (ng/mL) and free circumferential margins and capsule groups.

LINC00641 has been reported to be one of the 20 differentially expressed lncRNAs and mRNAs dysregulated through HOXA10 overexpression; for example, in one study, it showed downregulation with fold changes ≥ 2 and \( P < 0.05 \) (47). On the other hand, much evidence shows that several homeobox genes such as HOXA10 are dysregulated in cancers, significantly contributing to tumor progression. For example, Li et al. demonstrated that a decrease HOXA10 expression in endometrial carcinomas was significantly associated with increased tumor grade and was related to the modification of the HOXA10 promoter (48). Thus, it could be concluded that increased expression of LINC00641 may occur in cancers such as PC. Also, LINC00641 can act as a stimulant in the acute myeloid leukemia carcinogenic process, according to a recent study (49). Some study results are not in line with other findings. For example, Li et al. and Liang et al. reported that LINC00641 is acting as a tumor suppressor in bladder and glioblastoma patients, and a decrease in its expression was observed (50,51). Also, concerning breast and cervical cancer similar results have been attained (52,53). Therefore,
all the above studies suggest that the function of LINC00641 may vary depending on the type of cancer. In our study, LINC00641 expression in cancer samples showed a significant difference compared with BPH samples, indicating the strength of this marker in differentiating cancer from BPH (Fig. 1C). Despite a 60- to 70-fold increase in PCA3 expression in PC tumors compared to the normal tissues, one of its limitations included its failure to distinguish between the high and low-grade tumors. While in the present study, LINC00641 showed only a 1.7-fold increase in prostate tumors compared to the normal adjacent tissue, after categorizing samples into control and case groups in low GS in PC tissues, we were able to differentiate between the control and case in low grade with $P < 0.05$ (Fig. 1D). This suggests the importance of LINC00641 in early diagnosis.

There was no significant difference between clinicopathology subcategories in terms of LINC00641 expression. However, LINC00641 increasing expression trend was seen in the positive perineurial invasion, positive prostatic intraepithelial neoplasia, involved apex and base groups compared to negative perineurial invasion, negative prostatic intraepithelial neoplasia, free apex and base groups.

CONCLUSION

In conclusion, our investigation provides insights into the levels of JPX/LINC00641 expression in PC. We clarified that the expression of JPX is significantly lower and expression of LINC00641 is dramatically higher in PC tissues than in the adjacent noncancerous tissues and in relation to GS. The data presented here suggest that JPX/LINC00641 could be a novel component of gene signatures for the detection of PC. The limited sample size is one of the restrictions of our study. Hence, our findings should be validated in investigations with more cases in future research. According to our results, as well as recent findings, one single biomarker is insufficient and a panel of them might be required to assess PC diagnosis, prognosis, and management.

Acknowledgements

This study was financially supported by Vice-Chancellor of Research of Isfahan University of Medical Sciences, Isfahan, I.R. Iran through Grant No. 396123. The authors are grateful to all men who participated in this study at Imam Khomeini Medical Center. We would like to thank the staff of the Cancer Institute, Imam Khomeini Medical Center for their sincere cooperation. This project is a part of the thesis performed by RSS.

Conflict of interest statement

All authors declared no conflict of interest in this study.

Authors’ contribution

M.A. Tabatabaiee far and M.H. Modarressi contributed to the design of the work, interpretation of the results of the study, approval of the manuscript. R.S. Sajjadi performed the experiments and contributed to the analysis of the results and prepared the draft of the manuscript. The manuscript has been read and approved by all the authors.

REFERENCES

1. Hassanipour-Azgomi S, Mohammadian-Hafshejani A, Ghoncheh M, Towhidi F, Jamehshorani S, Salehiniya H. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate Int. 2016;4(3):118-124. DOI: 10.1016/j.prnil.2016.07.001.
2. Rigau M, Olivan M, Garcia M, Sequeiros T, Montes M, Colás E, et al. The present and future of prostate cancer urine biomarkers. Int J Mol Sci. 2013;14(6):12620-12649. DOI: 10.3390/ijms140612620.
3. Iczkowski KA, Lucia MS. Current perspectives on Gleason grading of prostate cancer. Curr Urol Rep. 2011;12(3):216-222. DOI: 10.1007/s11934-011-0181-5.
4. Epstein JI. An update of the Gleason grading system. J Urol. 2010;183(2):433-440. DOI: 10.1016/j.juro.2009.10.046.
5. Fine SW. Prostate Cancer Reporting on Biopsy and Radical Prostatectomy Specimens. In: Magi-Galluzzi C, Przybys CG, editors. Genitourinary Pathology. Springer; 2015. pp. 45-64. DOI: 10.1007%2F978-1-4939-2044-0.
6. Lai MHY, Luk WH, Chan JCS. Predicting bone scan findings using sPSA in patients newly diagnosed of
prostate cancer: feasibility in Asian population. Urol Oncol. 2011;29(3):275-279. DOI: 10.1016/j.uroonc.2009.05.007.7.

7. Kinoshita H, Shimizu Y, Mizowaki T, Takayama K, Norihisa Y, Kamoto T, et al. Risk factors predicting the outcome of salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy. Int J Urol. 2013;20(8):806-811. DOI: 10.1111/iju.12049.

8. Sharma S, Zapatero-Rodriguez J, O’Kennedy R. Prostate cancer diagnostics: clinical challenges and the ongoing need for disruptive and effective diagnostic tools. Biotechnol Adv. 2017;35(2):135-149. DOI: 10.1016/j.biotechadv.2016.11.009.

9. Taylor BS, Schultz N, Hieronymus H, Gopalan A, ncRNA. As: disruptive and effective

10. Chew CL, Lunardi A, Galluni F, Ruan DT, Chen M, Salmena L, et al. In vivo role of INPP4B in tumor and metastasis suppression through regulation of PI3K/AKT signaling at endosomes. Cancer Discov. 2015;5(7):740-751. DOI: 10.1158/2159-8290.CD-14-1347.

11. Azemikhah M, Ashtiani HA, Aghaei M, Rastegar H. Evaluation of discoidin domain receptor-2 (DDR2) expression level in normal, benign, and malignant human prostate tissues. Res Pharm Sci. 2015;10(4):356-363. PMID: 26600862.

12. Cheetham SW, Gruhl F, Mattick JS, Dinger ME. Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013;108:2419-2425. DOI: 10.1038/bjc.2013.233.

13. Han D, Wang M, Ma N, Xu Y, Jiang Y, Gao X. Long noncoding RNAs: novel players in colorectal cancer. Cancer Lett. 2015;361(1):13-21. DOI: 10.1016/j.canlet.2015.03.002.

14. Zhang Y, Xu Y, Feng L, Li F, Sun Z, Wu T, et al. Comprehensive characterization of IncRNA-mRNA related ceRNA network across 12 major cancers. Oncotarget. 2016;7(39):64148-64167. DOI: 10.18632/oncotarget.11637.

15. Yoon JH, Abdellahsen K, Gorospe M. Posttranscriptional gene regulation by long noncoding RNA. J Mol Biol. 2013;425(19):3723-3730. DOI: 10.1016/j.jmb.2012.11.024.

16. Tabatabaiefar MA, Sajjadi NR, Narrei S. Epigenetics and common non communicable disease. Adv Exp Med Biol. 2019;1121:7-20. DOI: 10.1007/978-3-030-10616-4_2.

17. Rönnau CGH, Verhaegh GW, Luna-Velez MV, Schalken JA. Noncoding RNAs as novel biomarkers in prostate cancer. Biomed Res Int. 2014;2014:591703,1-17. DOI: 10.1155/2014/591703.

18. Svoboda M, Slyskova J, Schneiderova M, Makovicky P, Bielik L, Levy M, et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis. 2014;35(7):1510-1515. DOI: 10.1093/carcin/bgu055.

19. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353-358. DOI: 10.1016/j.cell.2011.07.014.

20. Ghavimi R, Mohammadi E, Akbari V, Shafiee F, Jahaniian-Najafabadi A. In silico design of two novel fusion proteins, p28-IL-24 and p28-M4, targeted to breast cancer cells. Res Pharm Sci. 2020;15(2):200-208. DOI: 10.4103/1735-5362.283820.

21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001;25(4):402-408. DOI: 10.1006/meth.2001.1262.

22. Velonas VM, Woo HH, Remedios CG dos, Assinder SJ. Current status of biomarkers for prostate cancer. Int J Mol Sci. 2013;14(6):11034-11060. DOI: 10.3390/ijms140611034.

23. Kashi K, Henderson L, Bonetti A, Carninci P. Discovery and functional analysis of IncRNAs: methodologies to investigate an uncharacterized transcriptome. Biochim Biophys Acta. 2016;1859(1):3-15. DOI: 10.1016/j.bbagen.2015.10.010.

24. Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinformatics. 2016;14(1):42-54. DOI: 10.1016/j.gpb.2015.09.006.

25. Akbarian F, Tabatabaiefar MA, Shaygannejad V, Shahpouri MM, Badhian N, Sajjadi R, et al. Upregulation of MTOR, RPS6KB1, and EIF4EBP1 in the whole blood samples of Iranian patients with multiple sclerosis compared to healthy controls. Metab Brain Dis. 2020;35(8):1309-1316. DOI: 10.1007/s11011-020-00590-7.

26. Phin S, Moore M, Cotter PD. Genomic rearrangements of PTEN in prostate cancer. Front Oncol. 2013;3:240-248. DOI: 10.3389/fonc.2013.00240.

27. Crumbaker M, Khoja L, Joshua A. AR signaling and the PI3K pathway in prostate cancer. Cancers (Basel). 2014;6:1347-1361. DOI: 10.3390/cancers61114_2.

28. Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 2014;16(3):378-386. DOI: 10.4103/1088-868X.122876.

29. Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 2013;20(3):R83-R99. DOI: 10.1530/ERC-12-0394.

30. Farhan M, Wang H, Gaur U, Little PJ, Xu J, Zheng W. FOXO signaling pathways as therapeutic targets in cancer. Int J Biol Sci. 2017;13(7):815-827. DOI: 10.7150/ijbs.20052.
31. Asmarinah A, Paradowska-Dogan A, Kodaria R, Tanuhardja B, Waliszewski P, Mochtar CA, et al. Expression of the Bcl-2 family genes and complexes involved in the mitochondrial transport in prostate cancer cells. Int J Oncol. 2014;45(4):1489-1496. DOI: 10.3892/ijo.2014.2576.

32. Pietri E, Conteduca V, Andreis D, Massa I, Meleaggi E, Sarti S, et al. Androgen receptor signaling pathways as a target for breast cancer treatment. Endocr Relat Cancer. 2016;23(10):R485-R498. DOI: 10.1530/ERC-16-0190.

33. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, et al. Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem. 2011;112(1):78-88. DOI: 10.1002/jcb.22770.

34. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer. Genes Cancer. 2010;1(6):617-628. DOI: 10.1177/1947601910379132.

35. Chen Q, Zhou W, Han T, Du S, Li Z, Zhang Z, et al. MiR-378 suppresses prostate cancer cell growth through downregulation of MAPK1 in vitro and in vivo. Tumour Biol. 2016;37(2):2095-2103. DOI: 10.1007/s13277-015-3996-8.

36. Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, et al. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene. 2013;32(3):296-306. DOI: 10.1038/onc.2012.58.

37. Zhang Z, Sun J, Bai Z, Li H, He S, Chen R, et al. MicroRNA-153 acts as a prognostic marker in gastric cancer and its role in cell migration and invasion. Onco Targets Ther. 2015;8:357-364. DOI: 10.2147/OTT.S78236.

38. Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T, Calin GA. Long noncoding RNA in cancer and its role in cell migration and cancer. FEBS Lett. 2014;585(15):2514-2522. DOI: 10.1016/j.febslet.2014.06.023.

39. Tian D, Sun S, Lee JT. The long noncoding RNA, Jpx, is a molecular switch for X chromosome inactivation. Cell. 2010;143(3):390-403. DOI: 10.1016/j.cell.2010.09.049.

40. Chaligén R, Heard E. X-chromosome inactivation in development and cancer. FEBS Lett. 2014;588(15):2514-2522. DOI: 10.1016/j.febslet.2014.06.023.

41. Zhang L, Yang F, Yuan J, Yuan S, Zhou W, Huo X, et al. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis. 2013;34(3):577-586. DOI: 10.1093/carcin/bgs381.

42. Ma W, Wang H, Jing W, Zhou F, Chang L, Hong Z, et al. Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2017;41(2):163-170. DOI: 10.1016/j.clinre.2016.09.002.

43. Li J, Feng L, Tian C, Tang YL, Tang Y, Hu FQ. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22(23):8135-8144. DOI: 10.26355/eurrev_201812_16505.

44. Jin M, Ren J, Luo M, You Z, Fang Y, Han Y, et al. Long non-coding RNA JPX correlates with poor prognosis and tumor progression in non-small-cell lung cancer by interacting with miR-145-5p and CCND2. Carcinogenesis. 2020;41(5):634-645. DOI: 10.1093/carcin/bgz125.

45. Pan J, Fang S, Tian H, Zhou C, Zhao X, Tian H, et al. LncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/ß-catenin signaling. Mol Cancer. 2020;19(1):9-25. DOI: 10.1186/s12943-020-1133-9.

46. Yarmishyn AA, Kurochkin IV. Long noncoding RNAs: a potential novel class of cancer biomarkers. Front Genet. 2015;6:145-154. DOI: 10.3389/fgen.2015.00145.

47. Lin R, Zhao C, Jing L, Zhao S. Identification of LncRNAs/miRNAs related to endometrium function regulated by Homeobox A10 in Ishikawa cells. Cell Biol Int. 2015;39(7):842-851. DOI: 10.1002/cbi.10458.

48. Li B, Cao X, Weng C, Wu Y, Fang X, Zhang X, et al. HoxA10 induces proliferation in human prostate carcinoma PC-3 cell line. Cell Biochem Biophys. 2014;70(2):1363-1368. DOI: 10.1007/s12013-014-0065-7.

49. Wang J, Liu ZH, Yu LJ. Long non-coding RNA LINC00641 promotes cell growth and migration through modulating miR-378a/ZBTB20 axis in acute myeloid leukemia. Eur Rev Med Pharmacol Sci. 2019;23(17):7498-7509. DOI: 10.26355/eurrev_201909_18864.

50. Li Z, Hong S, Liu Z. LncRNA LINC00641 predicts prognosis and inhibits bladder cancer progression through miR-197-3p/ KLF10/PTEN/PI3K/AKT cascade. Biochem Biophys Res Commun. 2018;503(3):1825-1829. DOI: 10.1016/j.bbrc.2018.07.120.

51. Liang R, Zhi Y, Zheng G, Zhang B, Zhu H, Wang M. Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization. Onco Targets Ther. 2018;12:157-168. DOI: 10.2147/OTT.S171957.

52. Mao Q, Lv M, Li L, Sun Y, Liu S, Shen Y, et al. Long intergenic noncoding RNA 00641 inhibits breast cancer cell proliferation, migration, and invasion by sponging miR-194-5p. J Cell Physiol. 2020;235(3):2668-2675. DOI: 10.1002/jcph.29170.

53. Zhang Y, Yu R, Li L. LINC00641 hinders the progression of cervical cancer by targeting miR-378a-3p/CPEB3. J Gene Med. 2020;22(9):e3212. DOI: 10.1002/jgm.3212.